Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2019 Publisher: Aventis Pharma Limited, One Onslow Street, Guildford, Surrey, GU1 4YS, UK or trading as: Sanofi-aventis or Sanofi, One Onslow Street, Guildford, Surrey, GU1 4YS, UK
Tildiem 60mg Modified-Release Tablets.
Pharmaceutical Form |
---|
Modified release tablet. White, round, biconvex tablets engraved with’TILDIEM 60' or ‘DILT 60’ or ‘DTZ 60’ on one side. |
Each tablet contains 60mg of the active substance diltiazem hydrochloride.
Also contains 125.5mg of lactose monohydrate and 28mg of hydrogenated castor oil.
For a full list of excipients, see section 6.1.
Active Ingredient | Description | |
---|---|---|
Diltiazem |
Diltiazem is a calcium antagonist. It restricts the slow channel entry of calcium into the cell and so reduces the liberation of calcium from stores in the sarcoplasmic reticulum. This results in a reduction of the amount of available intracellular calcium reducing myocardial oxygen consumption. |
List of Excipients |
---|
Lactose monohydrate |
PVC/foil blister packs of 90 and 100 tablets. Securitainers, polypropylene body with polyethylene cap containing 50, 100 and 500 tablets.
Not all pack sizes may be marketed.
Aventis Pharma Limited, One Onslow Street, Guildford, Surrey, GU1 4YS, UK
or trading as: Sanofi-aventis or Sanofi, One Onslow Street, Guildford, Surrey, GU1 4YS, UK
PL 04425/0640
Date of first authorisation: 8 March 1984
Date of latest renewal: 23 September 2005
Drug | Countries | |
---|---|---|
TILDIEM | France, Italy, Netherlands, Tunisia, United Kingdom |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.